Fig. 3: In vivo PD, efficacy and tumour pharmacokinetics of AZD4320 and initial drug-dendrimer conjugates. | Communications Biology

Fig. 3: In vivo PD, efficacy and tumour pharmacokinetics of AZD4320 and initial drug-dendrimer conjugates.

From: Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Fig. 3

a Tumour growth inhibition of RS4;11 xenograft of AZD4320 (red) and initial AZD4320-dendrimer conjugates SPL-8931 (cyan), SPL-8932 (blue) and SPL-8933 (purple) (10 mg/kg or equivalent dose). Data in the graphs are represented as mean tumour volumes ±SEM (n = 6 per group). b Cleaved caspase in RS4;11 tumours measured by MSD ELISA (left axis) and tumour pharmacokinetics of AZD4320 (right axis) from single dose of AZD4320 (10 mg/kg) and dendrimer conjugates (equivalent to 10 mg/kg AZD4320). Data in the graphs are represented as mean (n = 2 per time point). c Tumours taken at 1, 5, and 24 h post dose were stained for CC3 by IHC (No sample taken from SPL-8931 treated animals at 1 h due to the long AZD4320 release half-life). Scale bar 500 µm.

Back to article page